Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a daily pill boost hair growth? new study seeks answers

NCT ID NCT07556016

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a dietary supplement containing taurine, L-cysteine, and grape seed extract to see if it improves hair health in people with hair loss. About 239 men and women will take either the active supplement or a placebo daily for 6 months. Researchers will measure hair density, shine, and strength at 3 and 6 months to see if the supplement works better than a placebo.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A dietary supplement containing taurine, L-cysteine, and grape seed extract (OPCs)
What this could lead to
If it works, this could offer a simple supplement option to improve hair density and reduce hair loss.
What could go wrong
This is an early-stage study with no phase, and results may show no benefit over placebo. The supplement is not a cure for hair loss.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

239 people

The number who actually took part.

Started

Nov 2025

Expected to finish

Jul 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Healthy subject and good general health * Man and woman * Between 18 and 65 years * Phototype II to IV (Fitzpatrick Classification scale) * BMI between 18.5 and 29.9 * With dark brown or black hair at the root * Subject agreeing to take the given Nutricosmetic: 2 capsules per day during 6 months and not introduce new nutritional supplement during the study. * Subject agreeing to not change sport activities (type and frequency of activities) throughout the entire course of the study * Subject agreeing to a stable diet with no change of dietary habits, e.g. no start a fasting cure throughout the entire course of the study * Subject agreeing to keep the same hair dyeing and frequency (if dyeing) during the whole study and at least from the previous month of starting. * Subject agreeing to keep the same shampoo frequency during all the whole study. * Subject with a stade IIIv or IV on the Hamilton scale amended by Norwood for men and with a grade I on the Ludwig scale for women. * Proportion of hair in telogen phase ≥ 20% for the men and ≥ 15% for the women. * Subject with a total hair density ≥ 150 hair/cm² on test area. * Subject agreeing to have one shaved zone of 1.2 x 1.5cm on the vertex area at each visit and during the whole study. * Subject accepting to have hair lock of about 135 hairs cut on D0 and M6 * Subject with a minimum hair length of 6 cm on the vertex and accepting to keep this minimum length during the study. * Having given freely and expressly his/her informed consent. * Psychologically able to understand the study related information and to give a written informed consent. * Affiliated to a health social security system. * Female of childbearing potential must use a medically accepted contraceptive regimen since at least 12 weeks before the beginning of the study and during all the study. * Female subjects of childbearing potential must have a negative pregnancy test at the inclusion. * Subject agreeing to no increase his/her cigarette and alcohol consumption during the study Exclusion Criteria: * Pregnant or nursing woman or planning a pregnancy during the study. * Subject with white or blond hair (coloured white hair also excluded to avoid affecting the PTG count); * Subject wearing a wig. * Subject with frizzy hair. * Subject having performed a hair bleaching or perm in the last 6 months or planned during the study. * Subject with modification of weight more than 5kg in the 2 months preceding the study and during the study, not using weight loss program or medication. * Subject having performed a visit to sauna or hammam in the 2 weeks preceding the study * Subject having wounds, moles, tattoos, scars, irritated skin… in the test areas that could influence the study. * Subject who had been deprived of their freedom by administrative or legal decision or who is under guardianship. * Major subject who is under guardianship or who is not able to express his/her consent. * Subject in a social or sanitary establishment. * Subject suspected to be non-compliant according to the investigator's judgment. * France only: Subject having received 6000 euros indemnities for participation in clinical research in the 12 previous months, including participation in the present study. * Subject enrolled in another clinical trial or which exclusion period is not over. * Intensive exposure to sunlight or UV-rays 1 month before the study or planned during the study. * Subject employed at the study site. * Subject with a condition or receiving a medication which, in the investigator's judgment, put the subject at undue risk. * Subject suffering from a severe or progressive disease (AIDS, HIV-positive, infection hepatitis, insulin dependent diabetes mellitus, epilepsy, chronic gastrointestinal disease…) or any other pathology that may interfere with the evaluation of the study results and/or subject safety at the investigator appreciation. * Subject having history of severe allergy or anaphylactic shock. * Subject having history of diabetes (type I or type II) * Subject having antecedent of cancer. * Subject with known hypersensitivity or allergy to one of the components of the products. * Subject with known history of or suffering from autoimmune disease and/or immune deficiency. * Subject having had surgery under general anaesthesia in the month preceding the start of the study. * Dermatological scalp disorders (ex: psoriasis, scalp dermatitis including seborrheic dermatitis, eczema, pre-cancerous or cancerous lesions, alopecia areata, fungal or bacterial infection, ringworm, lice or flea infestation) or poor hygiene. * Subject having skin disease on the head that requires actual topical medication or systemic drugs * Suffering from alopecia of special origins: chimiotherapy-induced (intoxication, drugs), or result from a chronic disease (genetic, endocrinological (excluding androgenetic alopecia)), immunological deficiencies…), result from injury or skin damage, alopecia of infectious origin (mycosis…), cicatricial alopecia, psychological disorders (trichotillomania, trichokryptomania). * Subject using minoxidil, finosteride, or other anti-hair loss treatment (including local hormonal treatment) within the past 6 months and during the study. * All other medical treatment (topic or per os) likely to interfere on hair growth or hair loss during the last 6 months prior the screening visit (including prostaglandins, rubefacients agents, all vasodilators, anti-androgens, all local hormonal treatment, silica, silicon, etc…); * Subject using anti-androgenic medications or drugs causing hypertrichosis (ex: phenytoin, acetazolamide, cyclosporine, diazoxide, psoralens, penicillamine, streptomycin, prostaglandins, vasodilatators and cortisone) or hypotrichosis (ex: anti-coagulants, retinoids, lithium and beta blockers) within the past 6 months and during the study. * Subject following a long period (\>30 days) treatment of anti-inflammatory during the last 4 months before the start of the study (screening) * Subject using any product having an action on hair loss, an anti-dandruff effect, fortifying effect or an effect on hair weakness within the 2 weeks before the study and during the study (shampoo, conditioner, leave on product applied by friction). Styling products (gel, hairspray, etc) are allowed during the study except on visit days with phototrichogram measurements. * Subject taking food supplements (including vitamins and minerals) or other active compounds which may have an effect on hair, scalp, skin, nail, … 2 months prior to the start of the study and throughout the entire course of the study * Subject having had hair implants, surgical intervention or aesthetic procedure for capillary correction or intending to have recourse to this surgery during the study. * Subject with application of a treatment (oral or topical) with tretinoin or isotretinoin or corticosteroid 8 weeks prior to the start of the study and/or throughout the entire course of the study * Subject with systemic therapy with immuno-suppressive drugs (e.g. corticosteroids) throughout the entire course of the study * Subject with systemic long-term therapy with anti-phlogistic agents or analgesics (e.g. diclophenac), except for minor pain relief medicine like acetylsalicylic acid or paracetamol within the last 3 days prior to the start of the study * Subjects using antibiotic medication within the 2 weeks before the study and during all the study duration

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Androgenetic alopecia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Eurofins Dermscan Pharmascan

    Aix-en-Provence, France, 13594, France

  • Eurofins Dermscan Pharmascan

    Villeurbanne, France, 69100, France

  • Eurofins EVIC

    Bordeaux, France, 33000, France

  • Eurofins Spincontrol

    Tours, France, 37000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.